Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment
Authors: Liang Kung Chen
Jean Woo
Prasert Assantachai
Tung Wai Auyeung
Ming Yueh Chou
Katsuya Iijima
Hak Chul Jang
Lin Kang
Miji Kim
Sunyoung Kim
Taro Kojima
Masafumi Kuzuya
Jenny S.W. Lee
Sang Yoon Lee
Wei Ju Lee
Yunhwan Lee
Chih Kuang Liang
Jae Young Lim
Wee Shiong Lim
Li Ning Peng
Ken Sugimoto
Tomoki Tanaka
Chang Won Won
Minoru Yamada
Teimei Zhang
Masahiro Akishita
Hidenori Arai
Seoul National University Bundang Hospital
Seoul Metropolitan Government - Seoul National University Borame Medical Center
National Yang-Ming University Taiwan
Ajou University, School of Medicine
National Center for Geriatrics and Gerontology - National Institute for Longevity Sciences
University of Tokyo
Veterans General Hospital-Kaohsiung Taiwan
Nagoya University School of Medicine
University of Tsukuba
Osaka University Faculty of Medicine
Veterans General Hospital-Taipei
Faculty of Medicine, Siriraj Hospital, Mahidol University
Peking Union Medical College Hospital
Chinese University of Hong Kong
Tan Tock Seng Hospital
Kyung Hee University
Beijing Hospital
Keywords: Medicine;Nursing
Issue Date: 1-Mar-2020
Citation: Journal of the American Medical Directors Association. Vol.21, No.3 (2020), 300-307.e2
Abstract: © 2019 AMDA – The Society for Post-Acute and Long-Term Care Medicine Clinical and research interest in sarcopenia has burgeoned internationally, Asia included. The Asian Working Group for Sarcopenia (AWGS) 2014 consensus defined sarcopenia as “age-related loss of muscle mass, plus low muscle strength, and/or low physical performance” and specified cutoffs for each diagnostic component; research in Asia consequently flourished, prompting this update. AWGS 2019 retains the previous definition of sarcopenia but revises the diagnostic algorithm, protocols, and some criteria: low muscle strength is defined as handgrip strength <28 kg for men and <18 kg for women; criteria for low physical performance are 6-m walk <1.0 m/s, Short Physical Performance Battery score ≤9, or 5-time chair stand test ≥12 seconds. AWGS 2019 retains the original cutoffs for height-adjusted muscle mass: dual-energy X-ray absorptiometry, <7.0 kg/m2 in men and <5.4 kg/m2 in women; and bioimpedance, <7.0 kg/m2 in men and <5.7 kg/m2 in women. In addition, the AWGS 2019 update proposes separate algorithms for community vs hospital settings, which both begin by screening either calf circumference (<34 cm in men, <33 cm in women), SARC-F (≥4), or SARC-CalF (≥11), to facilitate earlier identification of people at risk for sarcopenia. Although skeletal muscle strength and mass are both still considered fundamental to a definitive clinical diagnosis, AWGS 2019 also introduces “possible sarcopenia,” defined by either low muscle strength or low physical performance only, specifically for use in primary health care or community-based health promotion, to enable earlier lifestyle interventions. Although defining sarcopenia by body mass index–adjusted muscle mass instead of height-adjusted muscle mass may predict adverse outcomes better, more evidence is needed before changing current recommendations. Lifestyle interventions, especially exercise and nutritional supplementation, prevail as mainstays of treatment. Further research is needed to investigate potential long-term benefits of lifestyle interventions, nutritional supplements, or pharmacotherapy for sarcopenia in Asians.
ISSN: 15389375
Appears in Collections:Scopus 2020

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.